News and Press Releases
Formycon secures U.S. License Date for proposed Aflibercept Biosimilar FYB203 following settlement and license agreement with Regeneron
Formycon and its partners entered into a settlement and license agreement with Regeneron for FYB203/AHZANTIVE (Aflibercept-mrbb) Pending litigation at the U.S. District Court for the Northern District of West Virginia...
Category: Logistics, Other, Pharmaceutical
Posted: October 2, 2025
Biocon Biologics Secures U.S. Market Entry Date for Bosaya and Aukelso, Denosumab Biosimilars
1 October 2025 -- Bengaluru, India and New Jersey, US -- Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd, today announced a settlement and...
Category: Logistics, Other, Pharmaceutical
Posted: October 1, 2025
Biocon House, Semicon Park Electronics City, Phase – II, Hosur Road Bengaluru 560100, Karnataka, India
Rezon Bio launches as a European biologics CDMO combining cost efficiency and digital innovation.
New brand with proven track record – EMA and FDA-audited mirrored-capability sites in Poland provide an accelerated path from development to commercialization 29 September 2025 -- Gdańsk, Poland -- Rezon...
Category: BioManufacturing, Logistics, Manufacturing and Packing, Other, Pharmaceutical
Posted: September 29, 2025
Chiesi Completes Clinical Development Program for Carbon-Minimal Pressurized Metered-Dose Inhalers (pMDIs), Paving the Way for Regulatory Submissions
Successfully completed the TRECOS Phase III study, supporting the long-term safety of Chiesi’s carbon minimal pressurized metered dose inhaler (pMDI) platform Aiming to become the first pharmaceutical company to transition...
Category: Clinical Trials, Drug Delivery, Other, Pharmaceutical
Posted: September 26, 2025
eXmoor Pharma and Siam Bioscience form strategic partnership to establish leading Cell and Gene Therapy services in Southeast Asia
23 September 2025 -- Bristol, UK and Bangkok, Thailand -- eXmoor Pharma, the integrated cell and gene therapy CDMO with embedded consultancy expertise, and Siam Bioscience, a leading biopharmaceutical company...
Category: BioManufacturing, Manufacturing and Packing, Other, Pharmaceutical
Posted: September 23, 2025
Resolution Therapeutics announces first patient dosed in Phase I/II EMERALD study of RTX001 for the treatment of end-stage liver disease
RTX001 is the first engineered Regenerative Macrophage Therapy (RMT) to be evaluated in humans with advanced liver fibrosis First patient has successfully cleared safety period with no serious adverse events...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other
Posted: September 3, 2025
Centre for Regenerative Medicine, University of Edinburgh, 5 Little France Drive, Edinburgh, EH16 4UU
Celltrion opens new UK headquarters in Uxbridge, UK
New office located in the heart of Uxbridge underscores Celltrion’s long-term business commitment in the UK 17 June 2025 -- London, UK -- Celltrion UK has officially opened its new...
Category: Clinical Trials, Drug Discovery, Manufacturing and Packing, Other, Pharmaceutical
Posted: June 17, 2025
iOnctura commences randomized Phase I/II study in non-small cell lung cancer
First patient dosed in study investigating roginolisib + dostarlimab +/- docetaxel in patients with NSCLC who have progressed on prior immunotherapy/chemo Study will evaluate safety of the combination and explore...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: May 8, 2025
Campus Biotech Innovation Park Avenue Sécheron 15
1202 Genève
Switzerland
Neumora Therapeutics Reports Data from KOASTAL-1 Study of Navacaprant in Major Depressive Disorder
Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms as measured by MADRS total score compared to placebo Navacaprant showed an efficacy signal in...
Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: January 2, 2025
Bioxodes meets enrollment milestone in Phase 2a intracerebral hemorrhagic stroke trial
Bioxodes has enrolled first 16 patients in trial with BIOX-101 Completing treatment of first cohort of patients will trigger interim analysis BIOX-101 is a first-in-class drug candidate, a peptide developed...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: December 19, 2024
Exclusive UniSafe® distribution agreement between Owen Mumford and NIPRO exceeds expectations in Japan with new biosimilar launch
6 December 2024 - Oxford, UK – Owen Mumford, a global leader in medical devices, is pleased to announce that its exclusive agreement with Osaka-based NIPRO CORPORATION (NIPRO) to distribute...
Category: Drug Delivery, Manufacturing and Packing
Posted: December 6, 2024
ERS Genomics and Medicines Discovery Catapult sign CRISPR/Cas9 license agreement
Partnership provides Medicines Discovery Catapult access to CRISPR gene editing technology across a broad range of drug discovery applications 04 September 2024 – Dublin, Ireland, and Cheshire, UK – ERS...
Category: BioManufacturing
Posted: September 9, 2024
Touchlight and GSK Sign License Agreement for Use of Enzymatic dbDNA Production Technology for mRNA Manufacturing
Agreement enables GSK access to enzymatic production technology for rapid GMP production of DNA template for mRNA vaccine manufacturing 23 July 2024 -- Hampton, UK -- Touchlight, an innovation-driven CDMO...
Category: BioManufacturing, Biotechnology, Other, Pharmaceutical
Posted: July 23, 2024
Just – Evotec Biologics expands tech partnership for biosimilars with Sandoz
Just – Evotec Biologics expands partnership with Sandoz for development and commercial manufacturing of biosimilars Additional biosimilars potentially to be added to Sandoz development pipeline Further guarantees for Sandoz long-term...
Category: BioManufacturing, Biotechnology
Posted: July 10, 2024
Just – Evotec Biologics, Inc. 401 Terry Avenue North Seattle, WA 98109, US
Formycon receives FDA approval for FYB203/ AHZANTIVE) (aflibercept-mrbb), a biosimilar to Eylea
1 July 2024, Planegg-Martinsried, Germany - Formycon AG (FSE: FYB, “Formycon”) and its licencing partnerKlinge Biopharma GmbH ("Klinge") jointly announce that the U.S. Food and Drug Administration ("FDA")approved FYB203/AHZANTIVE (aflibercept-mrbb),...
Category: Pharmaceutical
Posted: July 1, 2024
